皮下英夫利西单抗CT-P13与维得利珠单抗进入临床实践:多利益相关方立场声明强调上市后研究需求
该立场声明基于公开数据,由45名比利时IBD医生经三轮改良Delphi流程制定皮下英夫利西单抗CT-P13与维得利珠单抗的使用声明,并纳入16例患者、9名护士和2名临床药理学家的意见,最终达成79条共识声明。声明提出转换至皮下制剂需满足临床与生物学缓解(克罗恩病)或临床与内镜缓解(溃疡性结肠炎),失应答时可考虑每周皮下注射或转回静脉制剂,转换应始终为共享决策。
要点
- 起始静脉治疗者,克罗恩病需临床与生物学双缓解、溃疡性结肠炎需临床与内镜双缓解才考虑转皮下制剂。
- 维持期标准剂量英夫利西单抗或维得利珠单抗且临床与内镜双缓解者,才考虑转皮下制剂。
- 失应答时可考虑每周皮下注射或转回静脉制剂,转换皮下制剂应始终为共享决策。
核心结论
- 所有利益相关方对皮下英夫利西单抗和维得利珠单抗持欢迎态度,但需要更多科学数据来选择适合转换的患者和时机,并探索失应答时的最佳策略。
研究设计与样本
- 基于公开数据的多利益相关方立场声明,由45名比利时IBD医生经三轮改良Delphi流程制定声明,16例IBD患者、9名IBD护士和2名临床药理学专家提供意见,至少70%IBD医生同意的声明被接受。
诊断标准与关键数值
- 起始静脉治疗者,仅考虑在达到临床与生物学双重缓解(克罗恩病)或临床与内镜双重缓解(溃疡性结肠炎)时转换为皮下制剂。
- 维持治疗者,仅考虑在标准剂量英夫利西单抗或维得利珠单抗治疗下达到临床与内镜双重缓解时转换为皮下制剂。
- 失应答时,可考虑每周皮下注射或转回静脉制剂。
- 转换为皮下制剂应始终为共享决策。
- 声明需获得至少70%的IBD医生同意方被接受。
临床应用与阅片要点
- IBD医生应考虑在起始静脉治疗达到临床与生物学双重缓解(克罗恩病)或临床与内镜双重缓解(溃疡性结肠炎)后转换至皮下制剂。
- 维持治疗达到临床与内镜双重缓解且接受标准剂量英夫利西单抗或维得利珠单抗者,可考虑转换至皮下制剂。
- 失应答时,IBD医生应考虑每周皮下注射或转回静脉制剂。
- 转换至皮下制剂应始终为共享决策。
局限性
- 许多关于皮下英夫利西单抗CT-P13和维得利珠单抗使用的问题仍未得到解答。
- 需要更多科学数据来选择适合转换至这些较新制剂的患者和时机。
- 需要更多科学数据来探索失应答时的最佳策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND AIMS: Although subcutaneous formulations of infliximab CT-P13 and vedolizumab are registered for treating moderate-to-severe inflammatory bowel disease [IBD], many questions on their use remain unanswered. We set up a multi-stakeholder initiative resulting in a position statement.
METHODS: Based on publicly available data, statements on subcutaneous infliximab and vedolizumab were developed and reviewed by 45 Belgian IBD physicians in a three-round modified Delphi process. During a consensus meeting, input from 16 IBD patients, nine IBD nurses and two clinical pharmacologists was provided and statements were further discussed, modified and scored. Statements achieving agreement by at least 70% of the IBD physicians were accepted.
RESULTS: The Delphi process resulted in 79 agreed statements. In patients initiating intravenous therapy, IBD physicians would only consider switching to subcutaneous formulations in patients achieving both clinical and biological response [for Crohn's disease] or both clinical and endoscopic response [for ulcerative colitis]. For patients under maintenance therapy, switching to subcutaneous formulations was only considered in those achieving both clinical and endoscopic response while receiving standard dosing of infliximab or vedolizumab. While awaiting more scientific data, IBD physicians should consider weekly subcutaneous injections or switching back to an intravenous formulation in case of loss of response. Finally, switching to a subcutaneous formulation should always be a shared decision.
CONCLUSIONS: All stakeholders welcomed subcutaneous infliximab and vedolizumab. However, more scientific data are needed to select the right patients and timing for switching to these newer formulations, and to explore the optimal strategy in case of loss of response.
引用
- Fierens L, Liefferinckx C, Hoefkens E, et al. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies. J Crohns Colitis. 2022. PMID: 35078228. doi:10.1093/ecco-jcc/jjac009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。